IDMA to add 2 more Chapters soon in Telengana and Karnataka

Hyderabad : Indian Drug Manufacturers' Association (IDMA) has asked the government that 'control samples' and samples given to physicians be exempted from duties and taxes in the budget. In a memorandum sent to the Finance Ministry, the ...

The Indian Pharmaceutical Association (IPA), Karnataka branch has highlighted regulatory roadblocks faced by pharmaceutical manufacturers in terms of compliance. The recent global regulatory charges against a few Indian companies have further ...

Concerned over the long delay in addressing the woes of the domestic manufactures, the Association of Indian Medical Device Industry (AIMED) has approached the ministry of health to take immediate measures to check growing import of these products.

The seventh annual general body meeting of the Consortium of Indian Pharmaceutical Manufacturers and Marketers Association (CIPMMA) held on June 22 at in Kodaikanal passed four resolutions including demand for introduction of general sales tax (GST) ...

The Ayurvedic Drug Manufacturers Association (ADMA) has called upon the government to intervene and politicise the issue of EU ban on herbal medicines at the earliest, so as to ensure that the stability and future of the industry is not threatened.

At a time when the international regulatory bodies are trying to crack the whip on Indian pharma manufacturers for various reasons including aseptic techniques and practices adopted in the production of drugs, injectables and vaccines, the ...

The findings of a survey of 1300 Indians from across 17 states conducted by AdvaMed an association of medical device manufacturers leading the effort to provide medical technology to the world reveals that although an overwhelming 72% of ...

June 2014 By Anthony Tridico , Partner, Jeffrey Jacobstein , Associate, and Leytham Wall , European patent attorney, Finnegan, Henderson, Farabow, Garrett & Dunner, LLP, USA As the global disease burden expands, the need for new, more ...

The Union budget left the pharma industry slightly disappointed as no specific measures were taken for drug manufacturers. What further upset them the other week was the price cap on products from two of its most important segments. While the impact ...